Recent News

• 03.27.2025 - Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
• 03.27.2025 - Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
• 03.10.2025 - Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
• 03.10.2025 - Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
• 03.04.2025 - Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.04.2025 - Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 02.25.2025 - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Recent Filings

• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 3 Initial statement of beneficial ownership of securities
• 03.10.2025 - 8-K Current report
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities